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Abstract
HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main
pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope
proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) such as Chloroquine and
Ammonium chloride (NH4Cl) are the weak bases and penetrate in lysosome as protonated form and increase the
intracellular pH. To investigate the antiviral effect of LA (Chloroquine and NH4Cl) on pH dependent endocytosis,
HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells. The
toxicological effects of Chloroquine and NH4Cl were tested in liver cells through MTT cell proliferation assay. For
antiviral screening of Chloroquine and NH4Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the
presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was
determined by using a luminometer. The results demonstrated that Chloroquine and NH4Cl showed more than
50% reduction of virus infectivity at 50 μM and 10 mM concentrations respectively. These results suggest that
inhibition of HCV at fusion step by increasing the lysosomal pH will be better option to treat chronic HCV.
Introduction
Hepatitis C Virus (HCV) is an enveloped, positive
stranded RNA virus classified in the family of Flaviviri-
dae. HCV causes acute and chronic hepatitis infection
which can eventually lead to permanent liver damage,
hepatocellular carcinoma and death. It is estimated that
three to four million people are infected with HCV every
year [1]. HCV genome encodes a single polyprotein pre-
cursor of just over 3000 amino acids. This polyprotein
precursor is co- and posttranslationally processed by cel-
lular (signal peptidase and signal peptide peptidase) and
viral (NS2-3 and NS3-4A) proteases to yield four struc-
tural (Core, E1, E2 and P7) and six non structural (NS2,
NS3, NS4A, NS4B, NS5A, NS5B) proteins. HCV envel-
ope is formed by E1 and E2 glycoprotein heterodimers
which are essential for virus entry into cells [2]. HCV E1
and E2 fusion was enhanced at low pH, suggesting that
HCV enters cells via the endosomal pathway and that E1
and/or E2 undergo conformational modifications that
allow fusion of viral and cellular membranes [3].
There are six major and more than 80 subtypes of
HCV. This classification is based on nucleotide variation
among different HCV isolates. They occur in different
proportion in different parts of the world. Genotype 1a
and 1b are the most common genotypes in the United
States and Europe [4,5]. The most prevalent HCV geno-
type in Pakistan is 3a followed by 3b and 1a [6].
Presently, there is no vaccine available for prevention of
HCV infection due to high degree of strain variation.
Current therapeutic options for hepatitis C are limited,
especially for genotype 1. For genotypes 2 and 3, pegy-
lated interferon in combination with ribavirin, can lead
to a sustained virological response in up to 80% of
patients [7]. However, this therapy is expensive and often
associated with side effects that may lead to discontinua-
tion of therapy [8]. Hemolytic anemia, cough, shortness
of breath & treatogenicity are the most common adverse
effect associated with ribavirin treatment, and muscle
aches, fatigue & neuropsychiatric adverse effects of IFN-
a lead to premature cessation of therapy in 10 to 20% of
patients [9,10]. Moreover, cost of interferon for 6 month
treatment ranging from PKR 50,000 to 150,000 is beyond
the financial range of most patients. Hence, there is a
need to develop anti HCV agents, which are less toxic,
more efficacious and cost-effective.
The term “lysosomotropic agent” was introduced by
DeDuve and co-workers (1974) to designate substances
that are taken up selectively into lysosomes. This defini-
tion leaves open the chemical nature of a lysosomotro-
pic substance and the mechanism of its uptake.
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methylamine penetrate acidic compartments of the cell
and accumulate as protonated forms, resulting in an
increase in the intravesicular pH [11-13].
Chloroquine, which is widely used for the treatment of
malaria, is a well-established inhibitor of autophagic
proteolysis which acts by inhibiting acidification of lyso-
somes and endosomes [14]. It has been reported that
lysosomotropic agents such as Chloroquine and NH4Cl
exert direct antiviral effects on several RNA viruses
including coronaviruses, flaviviruses and human immu-
nodeficiency virus (HIV) [15-18]. Moreover, clinical stu-
dies have demonstrated the safety, tolerability, and
efficacy of lysosomotropic agents in the antiviral treat-
ment of HIV infection [19,20].
In the current study HCV entry is blocked by Lysoso-
motropic agents. Firstly toxicological analysis of Chloro-
quine and NH4Cl were done in liver cells. After
toxicological analysis, antiviral effects were studied in
HCVpp of 1a and 3a genotype.
Materials and methods
Cell lines
Huh-7 and HEK 293 T cells were cultured in Dulbecco’s
Modified Eagle medium (DMEM) supplemented with
10% fetal calf serum, 100 IU/ml penicillin and 100 μg/
ml streptomycin, at 37°C in an atmosphere of 5% CO2.
Huh-7 was kindly provided by Dr. Zafar Nawaz (Bio-
chemistry and Molecular Biology Department, Univer-
sity of Miami, USA.
Plasmids
The pcDNA-E1E2 expression vector encoding the E1
and E2 glycoproteins (171-746) of HCV genotype 3a
and 1a, was generated by inserting into a nonpackage-
able, CMV promoter-driven expression construct. The
CMV-Gag-Pol murine leukemia virus (MLV) packaging
construct, encoding the MLV gag and pol genes, and
the pTG-Luciferase plasmid provided by Dr Jaean Dubi-
son, France.
Production of HCVpp and infection: Production of HCVpp
and infection
HCVpp were produced by co-transfection of 293-T cells
with equal amounts of three expression vector as
described previously [21]. Supernatants containing
HCVpp were harvested 48 h later, filtered through 0.45
μmp o r e - s i z e dm e m b r a n e sa n ds t o r e da t- 8 0 ° Cb e f o r e
use in infection of Huh7 cells.
Cell proliferation assay
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazo-
lium bromide) is a rapid and sensitive in-vitro procedure
for evaluating cellular toxicity of compounds. The MTT
substance is reduced by mitochondrial succinic dehydro-
genases in living cells to purple formazan crystals that
are not soluble in aqueous water. The absorption of dis-
solved formazan in the visible region correlates with the
number of viable cells [21]. To investigate cellular toxi-
city, 2 × 10
4 Huh-7 cells were plated into 96-well plates.
After 24 h, different concentrations of Chloroquine and
NH4Cl were added and the plate was sealed and kept at
37°C in an atmosphere of 5% CO2 for 24 h. After 24 h,
fresh media (100 μl) and MTT solution (5 mg/ml in
PBS) were added to all wells in Columns 1-11. Wrapped
the plate in aluminium foil and incubated for 3-4 h at
37°C. Media was carefully removed and added 100 μlo f
DMSO to dissolve the formazan crystals in Columns 1-
11. MTT formazan product was determined by measur-
ing absorbance with an enzyme-linked immunosorbent
assay (ELISA) plate reader at a test wavelength of 570
nm and a reference wavelength of 620 nm.
Cell viability was obtained using the following equa-
tion.
Percent cell viability =

Test 570 nm − 650nm/Control 570nm − 620nm

× 100
Antiviral analysis of Chloroquine and NH4Cl
To investigate anti-fusion effect of Chloroquine and
NH4Cl, Huh-7 cells were incubated in the presence or
absence of Chloroquine and NH4Cl at 37°C for 30 min.
After 30 min Huh-7 cells were infected with HCVpp of
3a and 1a genotype in the presence or absence of differ-
ent concentrations of Chloroquine and NH4Cl and incu-
bated for additional 24 h. After 24 h cells were lysed
and luciferase activity was determined by using a
luminometer.
Statistical Analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
significant.
Results
MTT Cell Proliferation Assay
MTT assay is a widely used test for evaluating cytotoxi-
city of compounds/herbs in cell cultures. The MTT sub-
stance is reduced by mitochondrial succinic
dehydrogenases in living cells to purple formazan crys-
tals that are not soluble in aqueous water. The absorp-
tion of dissolved formazan in the visible region
correlates with the number of alive cells [21]. Cytotoxic
effects of Chloroquine and NH4Cl were analyzed after
24 h incubation of Huh-7 cells with different
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proliferation of liver cells is unaffected at high concen-
tration. After toxicological analysis through MTT prolif-
eration assay, antiviral activities of Chloroquine and
NH4Cl were tested at non toxic concentrations.
HCVpp infection is pH dependent
Enveloped viruses enter cells through two main path-
ways: direct fusion at the plasma membrane and recep-
tor-mediated endocytosis. Fusion of the viral envelope
protein(s) is triggered by low pH within the endosome.
Lysosomotropic agents such as Chloroquine and NH4Cl,
have been used to demonstrate the pH sensitivity of
virus entry. We therefore tested the infectivity of
HCVpp after treatment of target cells with different
concentrations of Chloroquine and NH4Cl. HCVpp of
1a and 3a genotype demonstrated dose- dependent inhi-
bition in the presence of Chloroquine and NH4Cl.
Chloroquine and NH4Cl showed greater than 50%
reduction of virus infectivity at 50 μMa n d1 0m M
concentration respectively, suggesting a pH-sensitive
route of virus entry (Figure 2a and 2b).
Discussion
HCV entry is a multistep process requiring four cellular
receptor, fusion and endocytosis. HCV fusion depends
on E1 and E2, viral dose, and occurs within a specific
pH range. Targeting pH dependent endocytosis is a use-
ful tool to identify antiviral drugs against. A major
advancement to look into HCV entry process was the
development of HCVpp, consisting of native HCV
envelope glycoproteins, E1 and E2, assembled onto
Figure 1 Toxicological study of Chloroquine and NH4Cl in Huh-
7 cells: Huh-7 cells were plated at the density of 2 × 10
4 in 96 well
plates. After 24 h cells were treated with different concentrations of
chloroquine and NH4Cl and control consisted of solvent in which
compound dissolved. After 24 h incubation period add MTT
solution to all wells and incubated for 3-4 h at 37°C. Viable cells
convert MTT to purple formazan crystal. Added DMSO to dissolve
the formazan crystals and read absorbance at 570 nm and 620 nm.
(a) Toxicological analysis of Chloroquine in Huh-7 cells through MTT
cell proliferation assay. (b) Toxicological analysis of NH4Cl in Huh-7
cells through MTT cell proliferation assay.
Figure 2 Dose-dependent inhibition of HCVpp of 3a and 1a
genotype with lysosomotropic agents. HCVpp were produced in
HEK 293 T cells and collected in media after filtration in 0.45 micron
filter. Huh-7 cells were incubated in the presence or absence of
Lysosomotropic agents such as Chloroquine and NH4Cl at 37°C for
30 min. After 30 min Huh-7 cells were infected with HCVpp of 3a
and 1a genotype in the presence or absence of different
concentrations of lysosomotropic agents and incubated for
additional 24 h. After 24 h cells were lysed and luciferase activity
was determined by using a luminometer. Luciferase activity is not
reported as an absolute value, but is calculated relative to the ‘no
drug’ condition and reported on the y-axis as a percentage. Results
are represented as the average and standard error for three
independent experiments. (a) Dose-dependent inhibition of
Chloroquine against HCVpp of 1a and 3a genotype. (b) Dose-
dependent inhibition of NH4Cl against HCVpp of 1a and 3a
genotype. P value > 0.05 vs control was considered as statistically
significant.
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tially very powerful tool to identify and characterize
molecules that block HCV entry. In this study, HCVpp
of local HCV genotype 3a and 1a were produced to
study early entry steps mediated by HCV envelope gly-
coproteins. This assay is based on the quantification of
retroviral DNA synthesis, which occurs soon after the
fusion of the retroviral particle with a cellular mem-
brane. Presumably, this assay is only dependent on the
entry steps mediated by the heterodimer E1E2 (binding,
endocytosis, and fusion) and on the activity of the
reverse transcriptase of the HCVpp retroviral core.
The intracellular sub-compartments such as lysosomes
and endosomes have an acid nature with pH of about 5
[14]. Lysosomotropic agents such as Chloroquine and
NH4Cl are weak bases which have a tendency to accu-
mulate in these compartments. Lysosomotropic agents
are captured by protonation inside the lysosomes and
accumulate there (Figure 3). The ratio of intra/extra
lysosomal concentrations of these substances is equal to
the ratio of concentration of hydrogen ions in lysosomes
and in their vicinity, i.e. 1 : 100 if we suppose that pH
in lysosomes is 5 and in cytoplasm 7. The amount of
the permeable form of lysosomotropic agents passing
through the membrane depends on the substance pKa
v a l u ea n dp Hv a l u eo fs o l u t i o n .T h eh i g h e rt h ep K a
value, the lower the permeable form ratio. This has led
to the assumption that the specific uptake of lysosomo-
tropic substances into lysosomes depends on the acidic
pH of these compartments, ion-trapping weak bases
[13]. In this model, the most suitable weak bases are
those with a pKa around 8.
NH4Cl and Chloroquine are lysosomal weak bases that
are known to affect acid vesicles leading to dysfunction
of several proteins. Previous studies of Chloroquine and
Figure 3 Schematic model of lysosomal pH maintenance and
intrasomal trapping of lysosomal agents (LA) or weak bases.
Figure 4 Schematic representation of Inhibition of HCV by Increase the pH through Chloroquine and NH4Cl.
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mammalian cells in addition to the elevation of endoso-
mal pH, including the prevention of terminal glycosyla-
tion of immunoglobulin’s [24]. When added to virus-
infected cells, chloroquine inhibited later stages in vesi-
cular stomatitis virus maturation by inhibiting the glyco-
protein expression at the cell surface [25], and it
inhibited the production of infectious HIV-1 particles by
interfering with terminal glycosylation of the glycopro-
tein [26,27]. Increase in pH by Chloroquine and NH4Cl,
firstly inhibits low pH confirmational changes that trig-
gers fusion, penetration and uncoating and secondly
inhibits posttranslational modification of HCV envel-
oped proteins (E1 and E2) (Figure 4). Our results
demonstrated that, Chloroquine and NH4Cl inhibit
HCVpp entry in a dose-dependent manner at non toxic
concentration. Chloroquine and NH4Cl resulted in
greater than 50% reduction of virus infectivity at a con-
centration of 50 μM and 10 mM respectively, suggesting
a pH-sensitive route of virus entry (Figure 2a and 2b).
In conclusion, inhibition of HCV entry by increasing
the pH through lysosomotropic agents is an important
target to identified new drugs against HCV and combi-
nation of lysosomotropic agents with interferon will be
better option to treat chronic HCV.
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